2024
Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America
Strober B, Zhong Y, Sima A, Beeghly A, Eckmann T, Balagula E, Zhuo J, Lebwohl M. Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America. Journal Of Psoriasis And Psoriatic Arthritis 2024, 10: 22-27. PMID: 39583219, PMCID: PMC11583168, DOI: 10.1177/24755303241302070.Peer-Reviewed Original ResearchBody surface areaInternational Psoriasis CouncilSystemic therapySystemic psoriasis treatmentsDisease severity criteriaTopical therapyPsoriasis treatmentTherapy candidatesCorEvitas Psoriasis RegistrySystemic therapy initiationTreatment-naive patientsSeverity criteriaReal-world studyCross-sectional studyDisease severity indicatorsPatient-reported outcome measuresPlaque psoriasisPsoriasis RegistryTherapy initiationSystemic treatmentRegistry visitPASI scoreClinical characteristicsClinical decision-makingPsoriasis severityThe Association Between Patient-Reported Disease Burden and Treatment Switching in Patients with Plaque Psoriasis Treated with Nonbiologic Systemic Therapy
Patel V, Park S, Zhong Y, Sima A, Zhuo J, Roberts-Toler C, Becker B, Hovland S, Strober B. The Association Between Patient-Reported Disease Burden and Treatment Switching in Patients with Plaque Psoriasis Treated with Nonbiologic Systemic Therapy. Psoriasis Targets And Therapy 2024, 14: 167-174. PMID: 39624651, PMCID: PMC11610380, DOI: 10.2147/ptt.s478352.Peer-Reviewed Original ResearchPatient-reported disease burdenVisual analog scaleBiologic therapyPlaque psoriasisDisease burdenOdds ratioInitiation of biologic therapyQuality of lifeCorEvitas Psoriasis RegistryNonbiologic systemic therapyDisease severityPatient-reported burdenMultivariate logistic regression modelDermatology Life Quality IndexDays of enrollmentReal-world studyWork Productivity and Activity Impairment QuestionnaireLife Quality IndexPhysician-rated disease severityTherapy-naiveBiologic-naiveHealth-related quality of lifePsoriasis RegistrySystemic therapySkin pain51447 Long Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis: 2-year Results from the CorEvitas Psoriasis Registry
Armstrong A, Ferris L, Callis-Duffin K, Sima A, Eckmann T, Beeghly A, Photowala H, Patel M, Garg V, Strober B. 51447 Long Term Real-World Achievement of Skin Clearance Treatment Targets and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis: 2-year Results from the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2024, 91: ab59. DOI: 10.1016/j.jaad.2024.07.244.Peer-Reviewed Original ResearchCorEvitas Psoriasis RegistryMaintenance of responsePsoriasis RegistrySevere psoriasisTreatment targetSix-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
Lebwohl M, Strober B, Schrader A, Li A, Eckmann T, Zhu B, Malatestinic W, Birt J, Feely M, Blauvelt A. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. Drugs - Real World Outcomes 2024, 11: 451-464. PMID: 38914857, PMCID: PMC11365873, DOI: 10.1007/s40801-024-00439-w.Peer-Reviewed Original ResearchTumor necrosis factor inhibitorsInvestigator's Global AssessmentEffectiveness of ixekizumabDermatology Life Quality IndexDermatology Life Quality Index 0/1Body surface areaIL-23iCorEvitas Psoriasis RegistryIL-12/23iPatient-reported outcomesIL-17iPsoriasis RegistryBiologic therapySkin painSwitching to ixekizumabIL-23 inhibitorsDisease severityInterleukin-23 inhibitorAdjusted mean changesMultivariable modified Poisson regressionInterleukin-12/23 inhibitorsFollow-up visitConfidence intervalsModified Poisson regressionReal-world studyP176 Ixekizumab significantly improves nail disease and adjacent joint tenderness and swelling in psoriatic arthritis
McGonagle D, Kavanaugh A, McInnes I, Kristensen L, Merola J, Strober B, Bolce R, Lisse J, Pustizzi J, Sapin C, Ritchlin C. P176 Ixekizumab significantly improves nail disease and adjacent joint tenderness and swelling in psoriatic arthritis. Rheumatology 2024, 63: keae163.215. DOI: 10.1093/rheumatology/keae163.215.Peer-Reviewed Original ResearchPost-baseline assessmentTreatment effectsEli Lilly and CompanyPost Hoc AnalysisSevere functional impairmentStudy of adultsNail PsOFunctional impairmentAdjacent joint diseaseSPIRIT-H2HGroup levelHoc AnalysisPsoriatic arthritisJoint tendernessNail diseaseIndividual digitsPatients treated with ixekizumabNon-respondersEli LillyUCB PharmaJoint involvementJoint swellingCorEvitas Psoriasis RegistryCount scoreTreated with adalimumab
2023
Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy
Park S, Zhong Y, Sima A, Patel V, Zhuo J, Roberts-Toler C, Becker B, Hovland S, Strober B. Association of patient-reported disease burden and treatment switching among patients with plaque psoriasis on nonbiologic systemic therapy. SKIN The Journal Of Cutaneous Medicine 2023, 7: s113. DOI: 10.25251/skin.7.supp.113.Peer-Reviewed Original ResearchPatient-reported disease burdenNonbiologic systemic therapyPatient global assessmentVisual analog scaleDermatology Life Quality IndexBiologic therapySkin painPlaque psoriasisSystemic therapyPASI scoreDisease burdenIntroduction of biological treatmentsTreatment switchEQ-5D-3LDifficult-to-treat areasVisual analog scale measuresDegree of skin involvementCorEvitas Psoriasis RegistryDisease severityMultivariate logistic regression modelBody mass indexOdds of switchingSecondary analysisLife Quality IndexLesser burden
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply